Primecap Management Co. CA Takes $53.15 Million Position in Bruker Corporation $BRKR

Primecap Management Co. CA bought a new stake in shares of Bruker Corporation (NASDAQ:BRKR) during the 2nd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor bought 883,100 shares of the medical research company’s stock, valued at approximately $53,145,000. Primecap Management Co. CA owned approximately 0.58% of Bruker at the end of the most recent reporting period.

Other hedge funds have also added to or reduced their stakes in the company. Allworth Financial LP lifted its stake in Bruker by 40.6% in the third quarter. Allworth Financial LP now owns 890 shares of the medical research company’s stock valued at $29,000 after buying an additional 257 shares during the period. Federated Hermes Inc. increased its stake in shares of Bruker by 6.7% in the 4th quarter. Federated Hermes Inc. now owns 6,027 shares of the medical research company’s stock valued at $284,000 after acquiring an additional 380 shares in the last quarter. Parallel Advisors LLC increased its stake in shares of Bruker by 121.0% in the 4th quarter. Parallel Advisors LLC now owns 875 shares of the medical research company’s stock valued at $41,000 after acquiring an additional 479 shares in the last quarter. State of Michigan Retirement System lifted its position in shares of Bruker by 1.9% during the 1st quarter. State of Michigan Retirement System now owns 26,693 shares of the medical research company’s stock valued at $964,000 after acquiring an additional 500 shares during the period. Finally, CWM LLC lifted its position in shares of Bruker by 49.8% during the 4th quarter. CWM LLC now owns 1,631 shares of the medical research company’s stock valued at $77,000 after acquiring an additional 542 shares during the period. 79.52% of the stock is currently owned by institutional investors.

Analysts Set New Price Targets

BRKR has been the topic of a number of research analyst reports. Leerink Partners increased their price objective on shares of Bruker from $60.00 to $70.00 and gave the stock an “outperform” rating in a research report on Tuesday, July 7th. Citigroup reduced their price objective on Bruker from $60.00 to $53.00 and set a “hold” rating for the company in a research note on Wednesday, August 5th. Stifel Nicolaus set a $50.00 target price on Bruker in a research report on Wednesday, August 5th. Weiss Ratings upgraded Bruker from a “sell (d)” rating to a “sell (d+)” rating in a report on Wednesday, June 3rd. Finally, UBS Group set a $60.00 price target on shares of Bruker in a research report on Wednesday, June 24th. Two investment analysts have rated the stock with a Strong Buy rating, six have issued a Buy rating, four have issued a Hold rating and two have issued a Sell rating to the company. According to MarketBeat, Bruker presently has a consensus rating of “Moderate Buy” and an average target price of $56.64.

Bruker Stock Up 0.4%

BRKR stock opened at $57.06 on Thursday. The stock has a market cap of $8.69 billion, a P/E ratio of -81.51, a P/E/G ratio of 1.74 and a beta of 1.28. The company has a current ratio of 1.85, a quick ratio of 0.92 and a debt-to-equity ratio of 0.76. The stock’s fifty day simple moving average is $58.74 and its two-hundred day simple moving average is $47.82. Bruker Corporation has a 1-year low of $28.53 and a 1-year high of $65.30.

Bruker (NASDAQ:BRKR) last announced its earnings results on Tuesday, August 4th. The medical research company reported $0.49 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.38 by $0.11. The firm had revenue of $838.50 million during the quarter, compared to analyst estimates of $853.57 million. Bruker had a positive return on equity of 12.47% and a negative net margin of 2.35%.The business’s revenue was up 5.2% compared to the same quarter last year. During the same period last year, the firm posted $0.32 EPS. Bruker has set its FY 2026 guidance at 2.100-2.150 EPS. Analysts expect that Bruker Corporation will post 2.12 EPS for the current year.

Bruker Dividend Announcement

The company also recently announced a quarterly dividend, which will be paid on Wednesday, October 7th. Shareholders of record on Monday, September 21st will be given a $0.05 dividend. This represents a $0.20 dividend on an annualized basis and a yield of 0.4%. The ex-dividend date of this dividend is Monday, September 21st. Bruker’s dividend payout ratio (DPR) is currently -28.57%.

Bruker Company Profile

Bruker Corporation, founded in 1960 by physicist Günther Laukien and headquartered in Billerica, Massachusetts, is a leading developer and manufacturer of high-performance scientific instruments and analytical solutions. The company designs systems that enable molecular and materials research across academic, governmental, and industrial laboratories.

Bruker’s product portfolio encompasses nuclear magnetic resonance (NMR) spectrometers for molecular structure and dynamics studies, mass spectrometry platforms for proteomics and metabolomics, X-ray diffraction and scattering instruments for crystallography and materials characterization, atomic force and scanning probe microscopes for nanoscale surface analysis, as well as preclinical imaging systems such as micro-CT and MRI scanners.

In addition to hardware, Bruker provides software suites, applications support, training services, and long-term maintenance agreements to ensure optimal instrument performance.